Israeli pharmaceutical company Kamada Ltd. (KMDA) said Wednesday that it has closed its initial public offering in the United States of about 6.42 million ordinary shares at a price to the public of $9.25 per ordinary share.
All of the shares of common stock in the offering were offered by Kamada and include 837,395 shares issued pursuant to the over-allotment option granted to the underwriters, which was exercised in full.
Shares of Kamada's common stock began trading on the NASDAQ Global Select Market on May 31,
Morgan Stanley & Co. LLC and Jefferies LLC acted as the representatives of the underwriters and joint book-running managers for the offering. RBC Capital Markets, LLC and Oppenheimer & Co. Inc. acted as co-managers.
For comments and feedback: editorial@rttnews.com